RIN-PF-302 – Treprostinil Extension Study (Fibrotic Lung Disease)

An Open-label Extension Study of Inhaled Treprostinil in Subjects with Fibrotic Lung Disease

Who can take part?

You may be able to take part if you have previously been involved in the RIN-PF-305 study and:

• Completed all your study visits while taking the study medication; or
• Were still taking part when the study (or your participation) was stopped for reasons not related to safety.

You would not be eligible if you are pregnant or breastfeeding, or if the study doctor feels that taking part may not be safe for you.

What is involved?

This study is looking at the longer-term use of inhaled treprostinil.

• Study duration: Up to 6 years
• Clinic visits: One visit at Week 4, then every 12 weeks
• Phone calls: Monthly check-ins

You will remain in the study until the medication becomes commercially available for IPF or PPF, or until the study is stopped.

What will I need to do?

If you take part, you will be asked to:

• Take the study medication using a nebuliser four times a day
• Keep a simple diary to record when you take your doses
• Attend clinic visits for routine tests, which may include:
• • Questionnaires about your health
  • A heart tracing (ECG)
  • Blood tests
  • Breathing tests

More information

You can read more about this study here:
ClinicalTrials.gov – RIN-PF-302 Study